China has given the green light to an early-stage human test for a coronavirus vaccine candidate using German firm BioNTech's technology, its local partner said on Thursday.
A unit of Shanghai Fosun Pharmaceutical Group plans to initiate a phase I clinical trial of the potential shot, dubbed BNT162b1, developed with BioNTech's technology, "as soon as possible once it is ready", Fosun Pharma said in a filing.
Prior to the latest approval, Chinese researchers and companies have already moved eight vaccine candidates into different phases of human tests at home and abroad.
Also Read:
Fosun Pharma agreed in March to pay up toUSD 85 million in licensing fees to use BioNTech's proprietary mRNA technology and make an equity investment of USD 50 million for 1,580,777 ordinary shares in the German firm.
First Published: Jul 16, 2020 8:15 AM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
PM Modi visits Ram Mandir for first time since 'Pran Pratishtha', offers prayers before roadshow
May 5, 2024 8:59 PM
Visiting temples, obliging selfie requests, jabbing rivals – Kangana Ranaut is wooing voters on campaign trail
May 5, 2024 8:23 PM